Today: 10 June 2026
ASML stock rises ahead of Q4 earnings — here’s what investors are watching

ASML stock rises ahead of Q4 earnings — here’s what investors are watching

Amsterdam, Jan 27, 2026, 14:51 CET — Regular session.

  • ASML shares rose about 1% in Amsterdam ahead of Wednesday’s earnings report.
  • Broker notes from the past day stayed mostly supportive ahead of the earnings release.
  • The key question now: will ASML boost its 2026 sales forecast given the surge in AI-driven chip demand?

ASML shares rose around 1.1% to hover near 1,190 euros Tuesday, staying close to the day’s peak. Evercore ISI stuck to its buy rating, keeping a 1,300-euro price target as of Jan. 26. Barclays maintained its hold rating and a 1,200-euro target, according to .

ASML’s earnings release is set for tomorrow, and investors are keen to spot any tweaks in its 2026 outlook after the stock’s recent rally. The company, a key player in a tight slice of the AI supply chain, has analysts watching for an upgrade from its current forecast of flat-to-modest sales growth next year. John West at semiconductor consultancy Yole Group dubbed ASML’s extreme ultraviolet tools “the only game in town.” Meanwhile, Mizuho’s Kevin Wang pointed to possible “China business upside” for 2026. TechInsights senior fellow Dan Hutcheson warned that ditching ASML would be like “swapping a Formula One engine mid-race.” Reuters

This matters now because ASML’s order backlog and production forecast act as a bellwether for spending appetite among leading chipmakers. A small tweak to its guidance could ripple through the entire semiconductor equipment sector’s projections.

Lithography involves printing patterns onto silicon wafers using light in chip manufacturing. Extreme ultraviolet (EUV) lithography uses a shorter wavelength than deep ultraviolet (DUV), key for crafting the smallest features in cutting-edge chips, like those powering top-tier AI processors.

Traders aren’t focused solely on the quarter’s figures—they’re listening closely to the tone. They want clues on whether demand is rising beyond the AI-driven spike and any updates on how quickly ASML can ramp up output of its premier machines.

ASML is set to publish its Q4 and full-year earnings at 0700 CET on Wednesday. CEO Christophe Fouquet and CFO Roger Dassen will address the media at 1100 CET, followed by an investor call scheduled for 1500 CET, according to the company’s investor page.

Investors tend to focus on “order intake” — the new orders booked — instead of just the headline sales. This figure can swing wildly from quarter to quarter. A high order number might reflect timing quirks, whereas a low one could just signal customers delaying deliveries, not outright cancellations.

ASML faces competition from Japan’s Nikon and Canon, along with China’s SMEE, in the market for older DUV machines. Still, it remains the only supplier of EUV equipment for advanced chips. This unique position fuels the bullish case and accounts for the stock’s sharp moves whenever there are hints that major foundries or memory makers could scale back their investments.

After a strong run-up into earnings, the threat of a letdown is palpable. If management keeps a cautious tone for 2026, or if clients delay equipment deliveries and push orders out, the stock could slide fast—especially given the high bar already set.

Wednesday morning’s earnings and accompanying guidance will be the next major catalyst. Investors are focused on the 0700 CET announcement, eager to catch any signs from management about a more optimistic 2026 outlook—or whether they choose to stay cautious and keep expectations in check during the press conference and investor call.

Stock Market Today

  • Parabilis Medicines Raises $670 Million in Record-Breaking Biotech IPO
    June 10, 2026, 5:42 AM EDT. Parabilis Medicines raised a record $670 million in its initial public offering (IPO), making it the largest biotech listing to date. The cancer-focused company sold 33.5 million shares at $20 each, with a potential to increase proceeds by $100 million via underwriters' option. Parabilis aims to advance its lead candidate zolucatetide, targeting desmoid tumors, familial adenomatous polyposis, and other cancers, supported by FDA fast-track designation. The company also plans to invest $190 million in developing other drug candidates. Led by CEO Mathai Mammen, Parabilis leverages a novel helicon peptide platform to target previously undruggable proteins. The firm has secured substantial funding rounds since 2021 and recently partnered with Regeneron in a deal including $50 million upfront and $75 million equity investment.

Latest articles

DraftKings (DKNG) Moves After Prediction-Market News — Traders Focus on Stock

DraftKings (DKNG) Moves After Prediction-Market News — Traders Focus on Stock

10 June 2026
DraftKings shares soared 11.34% to $27.59 after revealing a 24% month-over-month jump in annualized consumer volume to $1.3 billion and a 34% rise in total volume traded to $3.1 billion in its Predictions product for May, based on preliminary, unaudited data, outpacing a falling Nasdaq and spotlighting investor focus on the product’s revenue potential and DraftKings’ strategic push.
Micron Stock’s $1 Trillion AI Test Is Here as Traders Look to June 24

Micron Stock’s $1 Trillion AI Test Is Here as Traders Look to June 24

10 June 2026
Micron shares fell 1.5% to $935.89 as the AI-chip rally cooled, despite bullish analyst calls and price targets up to $1,625; investors await the June 24 earnings report to see if tight memory chip supply and AI demand can sustain the stock’s trillion-dollar valuation amid broader market jitters and shifting sentiment.
Ondas Stock Comes Back Into the Spotlight After 13% Drop; Drone Trade Faces Fresh Challenge

Ondas Dips Premarket After 2.7 Million-Share Filing

10 June 2026
SoFi Technologies traded near $16.47 in early premarket, little changed as investors weighed its AI and digital asset product push against a risk-off market mood, with no fresh earnings news and inflation data looming that could impact rates, loan demand, and fintech valuations.
Ondas Dips Premarket After 2.7 Million-Share Filing

SoFi Stock Holds Ahead of Pre-Market Test as Wall Street Grows Defensive

10 June 2026
Rolls-Royce shares rebounded 1.5% in London after Tuesday’s 2.68% drop, as investors weighed fresh airline criticism over engine delays against the company’s reaffirmed 2026 profit and cash flow guidance; CEO Tufan Erginbilgic said Rolls had a “strong start to the year,” but risks remain if airline pressure leads to higher costs or slower cash conversion.
LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury

LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury

10 June 2026
LVMH shares slipped 0.49% to €489.90 in Paris after a four-day rebound, as investors weighed RBC’s reiterated Buy rating with a €600 target against ongoing 2026 losses and a 24% year-to-date drop; all eyes now turn to July’s first-half results for signs of recovery in Fashion & Leather Goods and any relief from Middle East weakness.
Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom
Previous Story

Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom

XRP price hovers near $1.90 as Fed decision nears, Ripple bank deals compete with macro nerves
Next Story

XRP price hovers near $1.90 as Fed decision nears, Ripple bank deals compete with macro nerves

Go toTop